Description of indications and clinical recommended groups of larotrectinib (Vitaika)

Larotrectinib is an oral reversible NTRK (neurotrophic receptor tyrosine kinase) fusion inhibitor specifically targeted at patients with solid tumors carrying NTRK gene fusions. It inhibits the proliferation and survival of tumor cells by blocking the TRK signaling pathway, thereby achieving anti-tumor effects. As a precision targeted drug, larotrectinib has shown significant efficacy in a variety of tumor types, especially for patients with NTRK fusion-positive tumors.

Larotrectinib is mainly applicable to all patients with solid tumors carryingNTRK gene fusion, regardless of tumor type or location. Its indications include patients with advanced or metastatic solid tumors and patients who are still at risk of recurrence after surgical resection. Due to its strong targeting, larotrectinib provides a new treatment option for patients with NTRK fusion-positive tumors for whom conventional chemotherapy or immunotherapy has limited effect.

Clinically, larotrectinib is recommended for patients who have been diagnosed with NTRK fusion positivity and have disease progression or failure to respond to standard treatments. The applicable population includes adult and pediatric patients, and its efficacy is good in different age groups. Patients need to confirm the NTRK fusion status through genetic testing before use to ensure the pertinence and efficacy of the medication.

During treatment, larotrectinib is usually administered orally and may be used as a single agent. To ensure efficacy and safety, patients are recommended to undergo regular imaging evaluation and laboratory monitoring, including liver function, blood routine, blood pressure and other indicators. For patients with unsatisfactory efficacy or drug resistance, the dose can be adjusted under the guidance of a doctor or combined with other treatment options to optimize the treatment effect and improve the quality of life.

Reference link:https://www.drugs.com

xa0